Good MorningSanta Claus experienced a bit of turbulence in the week leading up to the Christmas holiday but he was able to guide the market up to a new all-time high. The broad market S&P 500 was able to creep up and set a new high on Friday despite weakness in both the blue-chip Dow Jones Industrials and tech-heavy NASDAQ Composite.
The biggest news investors missed last week was the monthly reading of income and spending data. The data shows spending and incomes are on the rise but also a much-hotter than expected increase in inflation. Core inflation accelerated more than expected in November leaving the PCE Price index at the highest level in decades. With the FOMC already moving the timeline for rate hikes forward this news will surely force the committee to do so again.
Featured: Sell these "safe" blue chips immediately (Ad) 
|
Materials | |
Keep An Eye on These Gold Stocks Next Year
Gold is a commodity that has historically been viewed as a good hedge against inflation, which is why the precious metal’s price performance over the last year has been a bit puzzling. The SPDR Gold Shares ETF (NYSEARCA:GLD), which is intended to r... Read the Full Story |
|
From Our Partners | | Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief.
It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live. | | Watch the full story and see the verified track record for yourself |
|
Consumer Staples | |
A recent insider buy is only the latest reason to buy COST stock
Costco (NASDAQ:COST) shareholders were given yet another example of why timing is everything. Despite delivering a solid earnings report on December 9, COST stock is only up about 4%. But concerns about inflation, supply chain disr... Read the Full Story |
|
Finance | |
These 3 Stocks Could Outperform in 2022
With the new year right around the corner, investors might want to start thinking about the companies with the strongest prospects for 2022. There’s no better way to start off the year than by adding a few potential winners to your portfolio, but find... Read the Full Story |
|
From Our Partners | | Moderna's stock doubled in a single day after its cancer vaccine hit key Phase 3 goals, and Merck jumped too. But according to a former Steve Cohen fund manager, the next big opportunity is not Moderna or Merck.
It is a different kind of company tied to a technology already backed by Elon Musk, Sam Altman, Jeff Bezos, and Peter Thiel. Nvidia's Jensen Huang says it will have a dramatic impact on daily life, while Anthropic's CEO believes it could unlock a century of medical progress in just ten years.
Nature Magazine estimates its potential value at $367 trillion globally, and it is already rolling out across the United States. | | Click here to learn about this new era of medical technology |
|
Technology | |
Recent upgrades make a strong case for AAPL stock to move past its 52-week high
After not doing much of anything for most of the year, Apple (NASDAQ:AAPL) stock has made a strong move in the last two months of the year. As recently as October 13, 2021, AAPL stock was a market laggard being up ju... Read the Full Story |
|
Consumer Discretionary | |
Insider Selling In Carmax Ceases In Q4
Insiders were selling Carmax (NYSE: KMX) earlier this year but that activity has stopped. Insiders sold 925,010 shares during the first three quarters of the year but there has been no activity of record in the time since. The selling equals 0.57% of the sh... Read the Full Story |
|
From Our Partners | | Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required.
Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away. | | Discover the gold income fund before the next payout date |
|
Technology | |
Customer relation management (CRM) software company Salesforce.com (NYSE: CRM) stock has been plunging on its latest top and bottom-line guidance stemming from the fiscal Q3 2022 earnings call. While the fiscal Q3 2021 earnings were very strong, the lowered guidance shocked investors. Arguably, Sa... Read the Full Story |
|
Consumer Discretionary | |
Connected home fitness equipment maker and platform Peloton (NASDAQ: PTON) stock has been a nasty rollercoaster ride for investors. The popular connected fitness company bounced off $17.70 COVID lows to peak at $171.09 before plunging on the reopening trend back into the $30s. The Company has yet ... Read the Full Story |
|
Markets | |
Going into the new year, you may wonder what you should invest in: artificial intelligence, cyclical stocks, health care? A combination of these or something else entirely?
It's a great question. Based on the unique events from last year, rising interest rates and consumer pushes toward specific... Read the Full Story |
|
Consumer Discretionary | |
It’s that time of year for investors. Hopes for a Santa Claus rally, some much needed R&R, and yes—tax loss harvesting.
The annual ritual of dumping the year’s losers to offset capital gains taken early in the year is far from a festive event but can be a valuable part of ta... Read the Full Story |
|
Markets | |
Analysts are taking a more favorable view of T stock as the TimeWarner nears completion
AT&T (NYSE:T) stock is enjoying its best week since early summer. T stock is up 6.5% since December 16. The reason for the optimism is stemming from two analysts' upgrades. In both cases, the stock was up... Read the Full Story |
|
The Early Bird Stock Of The Day Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California. | | View Today's Stock Pick |
|
